Previous 10 | Next 10 |
Biogen Inc. (BIIB) is expected to report $3.97 for Q3 2023
2023-11-07 11:43:16 ET More on Biogen Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley 21st Annual ...
2023-11-07 08:30:19 ET More on Sage Therapeutics Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024 Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity Sage Therapeutics Q3 2023 Earnings Preview Sage granted FDA orphan...
2023-11-07 06:59:00 ET More on Biogen, Eisai, etc. Stocks To Watch: Tesla, Netflix, And AT&T Headline Big Week Of Earnings Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinic...
2023-11-05 23:46:57 ET In the upcoming week of November, investors can anticipate a flurry of quarterly reports from major companies, promising significant market activity. Notable among them is Disney ( NYSE: DIS ), a household name set to disclose its financial performance. ...
2023-11-03 15:00:40 ET More on the markets SPY: From Bullish To Bearish - Why The Bears Could Be Right This Time (Rating Downgrade) My View Of The S&P 500 November 2023 Edition (Technical Analysis) Famous Chart Pattern Returns To Life Six bullish stocks t...
2023-10-29 12:00:27 ET More on PBMs Cigna PBM unit Express Scripts sued for overcharging pharmacies FTC investigating purchasing organizations that work on behalf of PBMs Eli Lilly, Novo, Sanofi and leading PBMs accused in California over insulin prices CVS H...
2023-10-26 13:48:39 ET More on BioVie, Cognition, etc. BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade) Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Be...
2023-10-25 17:51:31 ET More on Biogen Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley 21st Annual ...
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical Improvement At 18 Months in Low-Tau Subpopulation in Additional Analysis of Clarity AD ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...